22 March 2018 - Cost regulators for NHS therapies in England and Wales have now published final guidelines backing the use of LEO Pharma’s Kyntheum as an option for treating severe plaque psoriasis.

Kyntheum (brodalumab), a novel biologic approved in Europe in July last year, is the first and only psoriasis treatment to target the IL-17 receptor.

By binding to this specific receptor on the cells of the skin, the drug blocks the biological activity of several pro-inflammatory IL-17 cytokines involved in plaque formation, offering a different mechanism of action to all other psoriasis biologics currently available, which target free inflammatory mediators.

Read Pharma Times article